A new report by visiongain predicts that the world market for multiple myeloma drug sales will reach $9.9bn in 2015. That revenue forecast and others appear in World Multiple Myeloma Drug Treatment Market 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK.
London, United Kingdom, September 20, 2012 –(PR.com)– Visiongain forecasts that the multiple myeloma treatment market will expand rapidly with the approval of new drugs. The market is already one of the most dynamic segments in oncology, revolutionised by the 2006 approval of Celgene’s Thalomid and then Revlimid, and Janssen’s Velcade. In July 2012, the market reached a new milestone with the approval of Onyx’s Kyprolis, a proteasome inhibitor with an improved safety profile and potential to be another blockbuster.
James Evans, a pharmaceutical industry analyst in visiongain, said: “The years 2012 to 2013 will see two important new products reach the market, Onyx’s Kyprolis and Celgene’s Actimid. Both of these have advantages over current drugs, but they’re basically incremental improvements on what we already have – proteasome inhibitors and immunomodulators.
“The next real shift for the market will come with the approval of newer mechanisms of action. Promising candidates in the pipeline include HDAC inhibitors, kinase inhibitors and orally-bioavailable second-generation proteasome inhibitors. However, perhaps the most exciting pipeline drug is elotuzumab by BMS and Abbott, a CS1 glycoprotein-targeting mAb, which has recorded high response rates in phase II trials. Behind elotuzumab, there are 30 or so other mAbs targeting this market, and they could make a major impact, alongside other new biologics.”
Visiongain’s report shows revenue forecasts to 2022 at overall world market, product and national level. Research, data and analyses cover activities of Celgene, Johnson & Johnson, Novartis, Onyx and other pharmaceutical and biotechnology companies.
That study discusses R&D and commercial news and predicts revenues to 2022 in leading national markets. The work analyses the US, Japan, Germany, France, the UK, Spain, Italy (EU5), Brazil, Russia, India and China (BRIC).
World Multiple Myeloma Drug Treatment Market 2012-2022 adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For sample pages and further information concerning the visiongain report The World Multiple Myeloma Drug Treatment Market 2012-2022 please visit www.visiongain.com/Report/895/World-Multiple-Myeloma-Drug-Treatment-Market-2012-2022
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.
+44 020 7336 6100